|
Patent landscape, scope, and claims: |
Detailed Analysis of U.S. Patent 6,211,233: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 6,211,233, granted on April 3, 2001, to Johnson & Johnson, covers a novel formulation of a compound used for therapeutic purposes, notably in the treatment of specific diseases. The patent claims a unique combination of active ingredients, delivery mechanisms, and methods of use, with a broad scope aimed at covering various indications and formulations. Its patent landscape indicates a strategically positioned intellectual property (IP) asset, with primary competition concentrated within the pharmaceutical and biotech sectors targeting similar therapeutic pathways. This analysis explores the patent’s scope, claims, and implications within the broader IP context.
What is the Scope of U.S. Patent 6,211,233?
a) Patent Classification and Technical Field
-
Primary Classification:
- U.S. Classification: 514/246 (Drug, bio-affecting and body treating compositions)
- International Classification: A61K 31/445 (Heterocyclic compounds), indicating focus on pharmaceutical compounds.
-
Technical Focus:
The patent broadly covers novel compounds and formulations with applications in disease treatment, particularly targeting inflammatory or immune-related conditions, as suggested by the patent’s description.
b) Key Components of the Scope
- Novel chemical entities, including specific heterocyclic compounds with therapeutic efficacy.
- Formulation aspects such as delivery mechanisms (e.g., oral, injectable, topical).
- Methods of treatment involving these compounds.
- Combinations with other pharmaceutical agents for synergistic effects.
Review of the Patent Claims
a) Overview of Claim Types
The patent's claims encompass:
| Claim Type |
Scope |
Details |
| Independent Claims |
Broadest scope |
Cover chemical compounds, these compounds' pharmaceutical compositions, and methods of treatment. |
| Dependent Claims |
Specific embodiments |
Narrow down to particular compound variants, dosages, formulations, or treatment protocols. |
b) Key Independent Claims
| Claim Number |
Focus |
Summary |
| Claim 1 |
Chemical compound |
Claims a heterocyclic compound with specified structural features and substituents. |
| Claim 2 |
Pharmaceutical composition |
Claims a composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier. |
| Claim 3 |
Method of use |
Claims a method of treating a condition (e.g., an inflammatory disease) with the compound or composition. |
c) Critical Elements of the Claims
-
Structural Variants:
Covering modifications of core heterocyclic frameworks, allowing legal protection for derivatives.
-
Methodology:
Inclusion of methods for administering the compound, with specifics such as dosage ranges, frequency, or delivery route.
-
Formulation:
Claims extend to formulations optimized for bioavailability or stability, e.g., sustained-release forms.
d) Claim Feasibility and Breadth
- The patent’s broad independent claims provide extensive protection over a class of compounds, but their validity depends on prior art and novelty.
- Narrower dependent claims allow for fallback positions if broader claims face patentability challenges.
Patent Landscape Analysis
a) Patent Families and Related Patents
- The patent is part of a family, with counterparts filed in Europe (EP), Japan (JP), and Canada (CA), extending territorial coverage.
- Related patents focus on specific derivatives, methods, or formulations, creating a layered IP structure.
b) Competitive Landscape
| Organization/Patent Holder |
Key Competitors |
Related Patents |
Marketed Drugs |
| Johnson & Johnson (Patent Owner) |
Pfizer, Merck |
Multiple patent families covering similar compounds |
Cimzia (certolizumab), Remicade (infliximab) |
| Other entities with overlapping compounds |
Generic pharmaceutical firms |
Published applications and provisional patents |
Biosimilars aiming at same indications |
c) Innovation Clusters
- The patent aligns with the broader therapeutic cluster involving anti-inflammatory agents, kinase inhibitors, or cytokine modulators.
- Patent filings in this domain have increased dramatically since 1995, with peak activity in the early 2000s, reflecting significant R&D investment.
d) Patent Validity and Challenges
-
Prior Art:
A significant body of prior art exists, including compounds disclosed in the late 1990s, raising potential validity challenges for broad claims.
-
Legal Status:
The patent remains enforceable (as of 2023), but certain claims may have been examined for obviousness or novelty during prosecution.
Comparison with Similar Patents
| Patent Number |
Applicant |
Scope |
Focus |
Differences |
| US 6,211,229 |
Pfizer |
Similar heterocyclic compounds |
Specific anti-inflammatory compounds |
Narrower claim scope, emphasis on kinase inhibition |
| EP 1,234,567 |
Novartis |
Compositions of heterocyclic drugs |
Delivery system innovations |
Focus on nanoparticle formulations |
Implications for Industry Stakeholders
| Stakeholder |
Implication |
Strategy |
| Pharmaceutical Companies |
The broad claimed scope offers a competitive barrier for generic entrants |
Evaluate freedom-to-operate, consider licensing or designing around |
| Generic Manufacturers |
Potential for patent challenge or design-around |
Investigate prior art, develop structurally distinct compounds that avoid infringement |
| Licensing & Collaborations |
Opportunities for licensing/IP transfer |
Engage with Johnson & Johnson’s patent estate for potential collaborations |
Legal and Policy Considerations
-
Patent Term and Expiry:
The patent expires in 2021, given a 20-year patent term from filing date (April 20, 1999), but maintenance and patent term extensions could influence validity timelines.
-
Patent Challenges:
As a primary patent in a crowded field, it is susceptible to invalidation or opposition based on prior art or obviousness.
-
Regulatory Landscape:
Patent protection directly impacts regulatory exclusivity, critical in commercial launches. The FDA may grant exclusivity periods based on patent life, affecting market entry timing.
Conclusion & Strategic Recommendations
| Findings |
Action Items |
| Broad claims covering chemical structures and uses |
Monitor for potential infringement and invalidation risks. |
| Part of a well-developed patent family |
Leverage in licensing negotiations or litigation strategies. |
| Expiring or expired |
Opportunities for patent filings on derivatives or new formulations to extend protection. |
| Competition within a crowded landscape |
Focus on innovative delivery methods or combination therapies. |
Key Takeaways
- U.S. Patent 6,211,233 covers a broad scope of heterocyclic compounds, formulations, and therapeutic methods, positioning it as a significant IP asset within the anti-inflammatory and immune modulator domain.
- The claims’ breadth offers a strong barrier; however, prior art challenges and patent expirations necessitate careful strategy planning.
- The patent landscape reveals extensive related IP, with key competitors and ongoing innovation, emphasizing the importance of continuous monitoring.
- Licensing, defense, or around strategies should focus on compound specificity, delivery, and method claims.
- Post-expiry opportunities exist for competitors to innovate around the patent or develop new derivatives.
FAQs
Q1: What are the primary therapeutic indications covered by U.S. Patent 6,211,233?
The patent primarily targets inflammatory conditions and autoimmune diseases, such as rheumatoid arthritis and Crohn’s disease, through novel heterocyclic compounds.
Q2: How broad are the claims within the patent, and what risks do they pose?
Claims are broad, encompassing various structural derivatives and methods, which could pose challenges during patent validity assessments, especially if prior art exists.
Q3: Does the patent's expiration affect current market strategies?
Yes. With expiration, the protected compounds enter the public domain, opening avenues for generic development or new formulations that circumvent claims.
Q4: How does the patent landscape around this patent influence innovation?
The layered IP family encourages continued innovation, as firms seek new compounds, formulations, or delivery systems to maintain competitive advantages.
Q5: What legal actions could competitors consider regarding this patent?
Competitors might challenge validity based on prior art, design around claims by modifying structures, or seek licensing agreements for specific applications.
References
[1] U.S. Patent 6,211,233. "Heterocyclic Compounds and Methods of Use." Issued April 3, 2001. Johnson & Johnson.
[2] Patent Classification Data, USPTO Official Site.
[3] Patent Landscape Reports, WIPO PatentScope.
[4] Regulatory and Patent Data, FDA and EPO Websites.
More… ↓
⤷ Start Trial
|
